Skip to content

Blog

Category: BioAgilytix Insight

BioAgilytix Team Q&A: Meet Eric Nesbit, Bioanalytical Project Manager/Scientist III

In this Q&A session we talk with Eric Nesbit, Bioanalytical Project Manager/Scientist III at BioAgilytix, to learn more about what led him to leave his…

Read More

Meet Jelle Hempenius, Business Development Director, Europe

Did you know that BioAgilytix’s ‘deep bench’ extends beyond those we have working in the lab? Many individuals in our operational departments, from business development…

Read More

510K Approved Assays vs. RUO Assays: Which Best Support Clinical Trial Biomarker Studies?

The answer to the question is “it depends”. Commonly a combination of 510K approved kits (in Europe known as assays that need to follow IVD-directive…

Read More

BioAgilytix Team Q&A: Meet Mike Losauro, Senior Business Development Director at BioAgilytix

Did you know that many of our team members have cross-functional background experience both in the lab and in customer-facing roles, making them uniquely equipped…

Read More

A History of Gene Therapy: Exploring Lessons Learned In Light of New Approvals

The FDA recently approved the first gene therapy for pediatric patients with SMA, signifying a major step forward for the therapeutic field as a whole.…

Read More

Key Takeaways from the 13th Annual WRIB, 2019

Last month at WRIB, our scientific team had the opportunity to participate in a number of discussions surrounding the latest topics of interest in biomarkers,…

Read More

The Fit for Flow Cytometry, Part 1: Ideal for Receptor Occupancy Assessment

Flow cytometry is an ideal platform for many applications involving the study of complex cell populations. In the first blog of our new “The Fit…

Read More

Key Takeaways from Oxford Global’s 14th Annual Biomarkers Congress

Couldn’t make the Oxford Global’s 14th Annual Biomarkers Congress? Read our recap of the key opportunities and challenges in biomarker development that scientists discussed.

Read More

Supporting a Gene Therapy Clinical Trial with Assay to Measure NAbs Against the AAV9 Serotype

Today we're featuring a case study on how BioAgilytix developed a cell-based assay to determine the prevalence of pre-existing antibodies against the AAV9 serotype in…

Read More

BioAgilytix Partnership Across Continents: Meet William Hunter and Todd Lester

With headquarters in the USA and Europe, effective team-wide communication is critical to our success. William Hunter, Director of BD & Global Key Accounts at…

Read More